AstraZeneca touts Movantik data in elderly; Novo weighs Victoza study in fatty liver;

@FiercePharma: Who are the top 10 advertisers in Big Pharma? Find out here. FiercePharmaMarketing feature | Follow @FiercePharma

@CarlyHFierce: No Namenda hard switch? No problem, Actavis execs say, with Namzaric on the horizon. More from FiercePharmaMarketing | Follow @CarlyHFierce

> AstraZeneca ($AZN) rolled out new study data showing that elderly patients using its bowel drug Movantik had a similar incidence of side effects as those on placebo or standard care. Report

> Novo Nordisk's ($NVO) diabetes med Victoza showed promise in patients with fatty liver disease, according to recent trial data, so the Danish drugmaker is weighing further study. Report

> China's Shanghai pharma has teamed up with online retailer to offer OTC drugs and other products online. Report

> Boehringer Ingelheim highlighted new data on its lung drug Ofev showing that it's effective and safe beyond 52 weeks of use. Report

Medical Device News

@FierceMedDev: ICYMI: Study: Remote monitoring of cardiac device patients results in better survival, less hospitalization. Article | Follow @FierceMedDev

@VarunSaxena2: The FierceBiotech panel: Top research execs tackle the fast-changing field of cancer drug R&D. Editor's corner | Follow @VarunSaxena2

@EmilyWFierce: Endo scoops up Par Pharma for $8B to gain ground in injectables. FiercePharma story | Follow @EmilyWFierce

> Tech industry group IEEE releases software security guidelines for medical devices. More

> Apollo's minimally invasive intragastric weight-loss balloon shows promise in clinical trial. Article

Biotech News

@FierceBiotech: Novo's liraglutide works in diabetes and obesity. How about NASH? Story | Follow @FierceBiotech

@JohnCFierce: $EBIO down 78% -- That's what you call an extinction level event. ELEven | Follow @JohnCFierce

> Boehringer strikes $250M deal for Phase I NASH drug. Story

> Sorrento dives into immuno-oncology under Soon-Shiong's shadow. Article

> A pair of Celgene partners gets on the FDA fast track. Report

Pharma Marketing News

> Diabetes app 'One Drop' drops with digerati backing. Article

> AZ bets big on biologics with $285M Swedish facility. Item

> Sanofi seeks the next Teenage Idol in meningitis vaccine campaign. More

> Can pharma + tech wearables be a match made in patient heaven? Story

> No Namenda hard switch? No problem, Actavis execs say, with Namzaric on the horizon. Report

Animal Health News

> Iowa biotech firm set to begin testing vaccine against deadly avian flu. Item

> Phibro records strong sales growth despite industry shift from antibiotics. Report

> ImmuCell enjoys spoils of success as demand for calf protector exceeds supply. More

> Jaguar's delayed and downsized IPO garners muted reception on Wall Street. Story

> FDA warns Lilly to stop marketing antibiotic for weight gain in pigs. Article

Biotech IT News

> GenomeDx shares 7 years of cancer testing data with medical center. Item

> Venter's HLI scoops samples from Cleveland Clinic as data-generating drive continues. More

> Allen Institute advances brain-mapping ambitions with cell-type database. Story

> Regeneron lobbying for its database to be the linchpin of Obama's Precision Medicine program. Article

> AstraZeneca dives into genetics of 80,000 samples in search of CV, diabetes insights. Report

And Finally... A major pharmacy chain in Venezuela has started fingerprinting customers in an attempt to stem the tide of medication shortages. Report